Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
STOCKHOLM, SVERIGE, 21 oktober 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget SVF Vaccines har presenterat positiva kliniska säkerhets- och...
-
STOCKHOLM, SWEDEN, October 21, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company SVF Vaccines, has presented positive clinical safety and immunogenicity...
-
STOCKHOLM, SVERIGE, 17 oktober 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar att portföljbolaget Umecrine Cognition kommer att presentera nya prekliniska data för golexanolon som...
-
STOCKHOLM, SWEDEN – October 17, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition will present new preclinical data on...
-
Aktieägarna i Karolinska Development AB (publ), org.nr 556707-5048, (“Karolinska Development” eller “Bolaget”), kallas till extra bolagsstämma onsdagen den 13 november 2024 kl. 11.00 hos Cirio...
-
The shareholders of Karolinska Development AB (publ), reg. no. 556707-5048, (“Karolinska Development” or the “Company”) are invited to the Extraordinary General Meeting (“EGM”), on Wednesday, November...
-
STOCKHOLM, SVERIGE 23 september 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar att bolaget säljer samtliga aktier i portföljbolaget Henlez ApS. Efter avyttringen består Karolinska...
-
STOCKHOLM, SWEDEN, September 23 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces the divestment of all its shares in the portfolio company Henlez ApS. Following the transaction,...
-
STOCKHOLM, 17 september 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget AnaCardio har slutfört den kliniska studien AC01-FE som genomförts i USA parallellt...
-
STOCKHOLM, SWEDEN September 17, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company AnaCardio has completed the AC01-FE study in the US and also...